Systemic tumor-cell reprogramming creates in situ immunotherapy biofactories
Researchers introduce LENTRA, an antigen-targeted lentiviral platform that genetically programs tumor cells to produce therapeutic molecules in situ.
Researchers introduce LENTRA, an antigen-targeted lentiviral platform that genetically programs tumor cells to produce therapeutic molecules in situ.